

Expres<sup>2</sup>ion Biotech Holding AB  
Press Release, 2018-05-03

---

## Expres<sup>2</sup>ion Biotech Holding AB: Publication of Annual Report for the fiscal year 2017

The Board of Directors and the Chief Executive Officer of Expres<sup>2</sup>ion Biotech Holding AB hereby publishes the Annual Report for the fiscal year 2017. The Annual Report and the accompanying Auditor's Report is available on the Company's website ([www.expres2ionbio.com](http://www.expres2ionbio.com)).

### Certified Adviser

Sedermora Fondkommission is appointed as Certified Adviser for Expres<sup>2</sup>ion Biotech Holding AB.

### For further information about Expres<sup>2</sup>ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: [sk@expres2ionbio.com](mailto:sk@expres2ionbio.com)

*This press release contains information that Expres<sup>2</sup>ion Biotech Holding AB is obligated to make public pursuant to the Securities Markets Act. The information was submitted for publication through the agency of the contact person set out above on May 3<sup>rd</sup>, 2018.*

---

### About Expres<sup>2</sup>ion

Expres<sup>2</sup>ion Biotechnologies ApS is a fully owned Danish subsidiary of Expres<sup>2</sup>ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, Expres<sup>2</sup>, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, Expres<sup>2</sup>ion develops novel VLP based vaccines through the joint venture AdaptVac ApS that was founded in 2017.